TY  - JOUR
A1  - Koch, Christine
A1  - Göller, Markus
A1  - Schott, Eckart
A1  - Waidmann, Oliver
A1  - Winkel, Mark op den
A1  - Paprottka, Philipp Marius
A1  - Zangos, Stephan
A1  - Vogel, Thomas
A1  - Bechstein, Wolf Otto
A1  - Zeuzem, Stefan
A1  - Kolligs, Frank Thomas
A1  - Trojan, Jörg
T1  - Combination of sorafenib and transarterial chemoembolization in selected patients with advanced-stage hepatocellular carcinoma: a retrospective cohort study at three german liver centers
T2  - Cancers
N2  - Background and Aims. Systemic treatment with sorafenib has been the standard of care (SOC) in patients with advanced Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) for more than a decade. TACE has been reported to allow better local tumor control in selected patients with BCLC stage C HCC. Methods. A retrospective analysis of patients with BCLC stage C HCC that were treated with sorafenib and TACE was conducted; they were compared to BCLC stage C patients treated either with TACE or sorafenib in the same period of time outside a clinical trial. Results. A total of 201 patients with BCLC stage C were identified, who were treated with either sorafenib and TACE (group A; n = 54), sorafenib (group B; n = 82) or TACE (group C; n = 65). No significant difference in baseline characteristics was observed. Time to progression was 7.0 months (95% CI: 4.3–9.7), 4.1 months (95% CI: 3.6–4.7) and 5.0 months (95% CI: 2.9–7.1) in groups A, B and C, respectively, and overall survival was 16.5 months (95% CI: 15.0–18.1), 8.4 months (95% CI: 6.0–10.8) and 10.5 months (95% CI: 7.5–13.6), respectively (group A vs. group B: p < 0.001; group A vs. group C: p = 0.0023). Adverse events of grade 3/4 occurred in 34% of patients in group A. Conclusions. Although sorafenib is a SOC in patients with BCLC stage C HCC, TACE is frequently used as an additional locoregional treatment in selected patients. This combined approach resulted in a significant overall survival benefit in selected patients, although randomized trials have not yet proven this benefit.
KW  - HCC
KW  - TACE
KW  - sorafenib
KW  - treatment
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62436
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-624367
SN  - 2072-6694
VL  - 13
IS  - 9, art. 2121
SP  - 1
EP  - 11
PB  - MDPI
CY  - Basel
ER  -